Core Viewpoint - The article discusses the development of a novel platform called CLIM-TIME, which integrates CRISPR screening and laser-captured microdissection to analyze the tumor microenvironment (TME) and its impact on T cell therapy response [2][3][5]. Group 1: Research Development - The CLIM-TIME platform combines CRISPR screening with laser microdissection, enabling systematic spatial analysis of the metastatic tumor microenvironment [3][5]. - This research reveals the causal relationship between intrinsic mutations in tumors and the spatial structure of the lung metastatic microenvironment, as well as the response to immunotherapy [3][6]. Group 2: Key Findings - The study identifies seven distinct subtypes of the metastatic tumor microenvironment and correlates them with immune status [6][7]. - The loss of tumor suppressor genes (TSGs) related to DNA repair and polycomb repressive complexes is associated with immune-infiltrated tumor microenvironments sensitive to T cell therapy [6][7]. - In contrast, the knockout of TSGs in the Hippo signaling pathway promotes the formation of a myeloid cell-rich tumor microenvironment that rejects T cells, leading to immune evasion and treatment resistance [6][7]. - Targeting the extracellular matrix crosslinking enzyme LOXL2 can effectively reshape the metastatic tumor microenvironment, enhancing T cell infiltration and improving treatment outcomes for various cancers with lung metastasis [6][7].